{"id":33118,"date":"2025-08-19T14:52:49","date_gmt":"2025-08-19T09:22:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33118"},"modified":"2026-03-13T09:48:23","modified_gmt":"2026-03-13T04:18:23","slug":"pharma-news-for-precigen-regenxbio-tonix","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix","title":{"rendered":"Precigen\u2019s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis; Tonix\u2019s Tonmya Becomes First FDA-Approved Fibromyalgia Treatment in Over 15 Years; FDA Extends BLA Review for REGENXBIO\u2019s RGX-121 in MPS II Patients; SystImmune\u2019s Izalontamab Brengitecan (EGFRxHER3 ADC) Gets FDA Breakthrough Designation for EGFR-Mutated NSCLC; Soligenix Granted FDA Orphan Drug Status to SGX945 for Beh\u00e7et&#8217;s Disease Therapy Following Phase II Success"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69dee1f2a24d1\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69dee1f2a24d1\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix\/#Precigens_PAPZIMEOS_Wins_Full_FDA_Approval_for_Recurrent_Respiratory_Papillomatosis\" >Precigen\u2019s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix\/#Tonixs_Tonmya_Becomes_First_FDA-Approved_Fibromyalgia_Treatment_in_Over_15_Years\" >Tonix\u2019s Tonmya Becomes First FDA-Approved Fibromyalgia Treatment in Over 15 Years<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix\/#FDA_Extends_BLA_Review_for_REGENXBIOs_RGX-121_in_MPS_II_Patients\" >FDA Extends BLA Review for REGENXBIO\u2019s RGX-121 in MPS II Patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix\/#SystImmunes_Izalontamab_Brengitecan_EGFRxHER3_ADC_Gets_FDA_Breakthrough_Designation_for_EGFR-Mutated_NSCLC\" >SystImmune\u2019s Izalontamab Brengitecan (EGFRxHER3 ADC) Gets FDA Breakthrough Designation for EGFR-Mutated NSCLC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix\/#Soligenix_Granted_FDA_Orphan_Drug_Status_to_SGX945_for_Behcets_Disease_Therapy_Following_Phase_II_Success\" >Soligenix Granted FDA Orphan Drug Status to SGX945 for Beh\u00e7et&#8217;s Disease Therapy Following Phase II Success<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-precigen-s-papzimeos-wins-full-fda-approval-for-recurrent-respiratory-papillomatosis\"><span class=\"ez-toc-section\" id=\"Precigens_PAPZIMEOS_Wins_Full_FDA_Approval_for_Recurrent_Respiratory_Papillomatosis\"><\/span>Precigen\u2019s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Precigen, Inc.<\/strong> announced that the FDA has granted full approval to <strong>PAPZIMEOS (zopapogene imadenovec-drba)<\/strong> for the treatment of adults with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/recurrent-respiratory-papillomatosis-market\" class=\"ek-link\">recurrent respiratory papillomatosis (RRP)<\/a>.<\/strong> The decision makes PAPZIMEOS the first and only FDA-approved therapy for RRP, a rare and debilitating disease caused by <strong>chronic HPV 6 <\/strong>or<strong> HPV 11 infection.<\/strong> Unlike previous accelerated approvals, the agency\u2019s decision does not require a confirmatory trial, underscoring the strength of the pivotal data.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cFor more than a century, patients with RRP have relied on repeated surgeries to manage this relentless condition. Today marks a historic turning point,\u201d said Helen Sabzevari, PhD, President and CEO of Precigen. \u201cWith the landmark approval of PAPZIMEOS, adult patients now have access to the first therapy that targets the root cause of the disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>RRP, which affects an estimated 27,000 adult patients in the U.S., often leads to severe voice disturbance, airway compromise, and recurrent infections. Current management has centered on repeated surgical removal of tumors, a burdensome approach that does not prevent recurrence. PAPZIMEOS, a non-replicating adenoviral vector-based immunotherapy, is administered through four subcutaneous injections over 12 weeks and is designed to elicit an immune response against papilloma cells expressing HPV 6\/11 proteins.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis long-awaited FDA approval represents a momentous milestone for the RRP community,\u201d said Kim McClellan, President of the Recurrent Respiratory Papillomatosis Foundation. \u201cFor the first time, adult patients with RRP have access to an FDA-approved therapy that offers the potential to reduce\u2014or even eliminate\u2014endless repeated surgeries.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The approval was supported by data from a pivotal open-label, single-arm study in adults with RRP. Results showed that 51% of patients achieved a Complete Response, requiring no surgeries in the 12 months following treatment, with durability beyond 24 months in many cases. PAPZIMEOS was well-tolerated, with no dose-limiting toxicities or treatment-related adverse events greater than Grade 2.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tonix-s-tonmya-becomes-first-fda-approved-fibromyalgia-treatment-in-over-15-years\"><span class=\"ez-toc-section\" id=\"Tonixs_Tonmya_Becomes_First_FDA-Approved_Fibromyalgia_Treatment_in_Over_15_Years\"><\/span>Tonix\u2019s Tonmya Becomes First FDA-Approved Fibromyalgia Treatment in Over 15 Years<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Tonix Pharmaceuticals Holding Corp.<\/strong> announced that the FDA has approved <strong>Tonmya (cyclobenzaprine HCl sublingual tablets) <\/strong>for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/fibromyalgia-market\"><strong>fibromyalgia in adults<\/strong><\/a>. Tonmya, a first-in-class, non-opioid bedtime analgesic, is the first new therapy for fibromyalgia in more than 15 years, addressing a major unmet need for millions of patients in the U.S.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA approval of Tonmya as a first-line treatment represents a landmark advancement for people living with fibromyalgia,\u201d said Seth Lederman, M.D., CEO of Tonix Pharmaceuticals. \u201cBy targeting nonrestorative sleep, a hallmark of this condition, Tonmya has the potential to provide meaningful relief and improve quality of life for patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Fibromyalgia affects more than 10 million adults in the U.S., primarily women, and is marked by chronic pain, fatigue, and sleep disturbances. The FDA\u2019s decision was supported by two pivotal Phase III randomized trials involving nearly 1,000 patients, where Tonmya significantly reduced daily pain scores versus placebo and demonstrated meaningful improvements in patient-reported outcomes. Across more than 1,400 patients evaluated in Phase III studies, the drug was generally well tolerated.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cFor over 15 years, this community has been underserved and waiting for new treatment options,\u201d said Sharon Waldrop, founder of the Fibromyalgia Association. \u201cThis approval is a promising step forward and brings renewed hope to millions who live with this painful and exhausting condition.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Tonmya is expected to be available for U.S. adult patients with fibromyalgia beginning in the fourth quarter of this year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-extends-bla-review-for-regenxbio-s-rgx-121-in-mps-ii-patients\"><span class=\"ez-toc-section\" id=\"FDA_Extends_BLA_Review_for_REGENXBIOs_RGX-121_in_MPS_II_Patients\"><\/span>FDA Extends BLA Review for REGENXBIO\u2019s RGX-121 in MPS II Patients<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>REGENXBIO Inc.<\/strong> announced that the FDA has extended its review timeline for the<strong> Biologics License Application (BLA)<\/strong> of clemidsogene lanparvovec (RGX-121), an investigational one-time gene therapy for <a href=\"https:\/\/www.delveinsight.com\/report-store\/mucopolysaccharidosis-ii-market\"><strong>Mucopolysaccharidosis II (Hunter syndrome)<\/strong><\/a>. The Prescription Drug User Fee Act (PDUFA) goal date has been moved from November 9, 2025, to February 8, 2026, following the submission of additional long-term clinical data.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cBoys with this rare, devastating disease have no treatment options to address neurodevelopmental decline, and the <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-market\"><em>Hunter syndrome<\/em><\/a><em> community is in urgent need of a therapeutic option with the potential to improve these patients&#8217; lives,\u201d said Curran M. Simpson, President and Chief Executive Officer of REGENXBIO. \u201cWe promptly provided the FDA with the information requested, and our commercial launch plans remain on track.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The extension is based on the company\u2019s submission of positive 12-month clinical results from all 13 patients in the pivotal study of RGX-121. These outcomes are consistent with earlier biomarker and neurodevelopmental data and will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM) in September 2025.<\/p>\n\n\n\n<p>RGX-121 has already received multiple regulatory designations, including Orphan Drug Product, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) status from the FDA, along with ATMP classification from the European Medicines Agency. No safety concerns have been raised during the FDA\u2019s review or inspections to date.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-systimmune-s-izalontamab-brengitecan-egfrxher3-adc-gets-fda-breakthrough-designation-for-egfr-mutated-nsclc\"><span class=\"ez-toc-section\" id=\"SystImmunes_Izalontamab_Brengitecan_EGFRxHER3_ADC_Gets_FDA_Breakthrough_Designation_for_EGFR-Mutated_NSCLC\"><\/span>SystImmune\u2019s Izalontamab Brengitecan (EGFRxHER3 ADC) Gets FDA Breakthrough Designation for EGFR-Mutated NSCLC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>SystImmune Inc. and Bristol Myers Squibb <\/strong>announced that the FDA has granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> to <strong>izalontamab brengitecan (iza-bren)<\/strong> for the treatment of patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><strong>locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/strong><\/a><strong> <\/strong>harboring EGFR exon 19 deletions or exon 21 L858R mutations whose disease has progressed after EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA\u2019s granting of Breakthrough Therapy Designation underscores the potential of iza-bren to meaningfully improve clinical outcomes for patients with previously treated EGFR-mutant NSCLC,\u201d said Dr. Jonathan Cheng, Chief Medical Officer of SystImmune. \u201cThe data we have generated to date suggest that iza-bren could address a critical unmet need, and we look forward to working closely with the FDA to advance development.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Iza-bren is a potential first-in-class bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, carrying a topoisomerase I inhibitor payload. Developed by Biokin in China and jointly advanced by SystImmune and Bristol Myers Squibb outside China, the therapy aims to address the lack of effective options for patients whose disease progresses following frontline EGFR TKI therapy and platinum chemotherapy.<\/p>\n\n\n\n<p>The FDA\u2019s decision was supported by efficacy and safety results from three ongoing trials: BL-B01D1-101 and BL-B01D1-203 in China, and the global BL-B01D1-LUNG-101 study across the U.S., Europe, and Japan. Collectively, these studies demonstrated promising clinical activity and a manageable safety profile in heavily pretreated EGFR-mutant NSCLC patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-soligenix-granted-fda-orphan-drug-status-to-sgx945-for-behcet-s-disease-therapy-following-phase-ii-success\"><span class=\"ez-toc-section\" id=\"Soligenix_Granted_FDA_Orphan_Drug_Status_to_SGX945_for_Behcets_Disease_Therapy_Following_Phase_II_Success\"><\/span>Soligenix Granted FDA Orphan Drug Status to SGX945 for Beh\u00e7et&#8217;s Disease Therapy Following Phase II Success<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Soligenix, Inc.<\/strong> announced that the FDA has<strong> granted orphan drug designation<\/strong> to <strong>dusquetide<\/strong>, the active ingredient in <strong>SGX945<\/strong>, for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/behcets-disease-market\"><strong>Beh\u00e7et\u2019s Disease<\/strong><\/a><strong>.<\/strong> The decision follows positive Phase IIa results demonstrating biological efficacy and safety in patients with oral ulcers caused by the rare autoimmune disorder.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cBeh\u00e7et&#8217;s Disease is an area of unmet medical need, with as many as one million people worldwide affected by this incurable condition,\u201d said Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. \u201cGiven the meaningful improvements seen in our proof-of-concept trial, we are hopeful dusquetide can play a role in helping underserved patients. The FDA\u2019s orphan designation is an important milestone as we continue to advance SGX945.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Under the U.S. Orphan Drug Act, therapies that receive orphan designation are eligible for incentives, including seven years of market exclusivity upon approval, tax credits, potential grant funding, and waiver of FDA user fees.<\/p>\n\n\n\n<p>The Phase IIa study of SGX945 in Beh\u00e7et\u2019s Disease patients showed encouraging efficacy in treating oral aphthous ulcers, a hallmark symptom that contributes significantly to the disease burden. Soligenix plans to leverage orphan designation benefits to accelerate clinical development and strengthen its intellectual property position around dusquetide.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Precigen\u2019s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis Precigen, Inc. announced that the FDA has granted full approval to PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). The decision makes PAPZIMEOS the first and only FDA-approved therapy for RRP, a rare and debilitating disease caused by chronic HPV [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":33120,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[20156,20161,20157,20158,204,704,17530,303,12926,12925,349,21683,420,6733,979,12555,12554,6732,21479,12557,639,5789,22403],"industry":[17225],"therapeutic_areas":[17238,17227,17245,17228,17243],"class_list":["post-33118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-behcets-syndrome","tag-behcets-syndrome-therapies","tag-behcets-syndrome-treatment","tag-behcets-syndrome-treatment-market","tag-delveinsight","tag-fda","tag-fibromyalgia","tag-hunter-syndrome","tag-hunter-syndrome-market","tag-hunter-syndrome-pipeline","tag-latest-pharma-news","tag-mucopolysaccharidosis-iii","tag-news","tag-non-small-cell-lung-cancer","tag-non-small-cell-lung-cancer-nsclc","tag-non-small-cell-lung-cancer-market","tag-non-small-cell-lung-cancer-market-insights","tag-non-small-cell-lung-cancer-pipeline","tag-non-small-cell-lung-cancer-treatment","tag-non-small-cell-lung-cancer-treatment-market","tag-pharma-news","tag-recent-pharma-news","tag-recurrent-respiratory-papillomatosis","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Precigen, REGENXBIO, Tonix<\/title>\n<meta name=\"description\" content=\"Precigen\u2019s PAPZIMEOS; Tonix\u2019s Tonmya; REGENXBIO\u2019s RGX-121; SystImmune\u2019s Izalontamab Brengitecan; Soligenix\u2019s SGX945\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Precigen, REGENXBIO, Tonix\" \/>\n<meta property=\"og:description\" content=\"Precigen\u2019s PAPZIMEOS; Tonix\u2019s Tonmya; REGENXBIO\u2019s RGX-121; SystImmune\u2019s Izalontamab Brengitecan; Soligenix\u2019s SGX945\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T09:22:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-13T04:18:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/19145158\/19-08-2025-feature.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Precigen, REGENXBIO, Tonix","description":"Precigen\u2019s PAPZIMEOS; Tonix\u2019s Tonmya; REGENXBIO\u2019s RGX-121; SystImmune\u2019s Izalontamab Brengitecan; Soligenix\u2019s SGX945","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Precigen, REGENXBIO, Tonix","og_description":"Precigen\u2019s PAPZIMEOS; Tonix\u2019s Tonmya; REGENXBIO\u2019s RGX-121; SystImmune\u2019s Izalontamab Brengitecan; Soligenix\u2019s SGX945","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-08-19T09:22:49+00:00","article_modified_time":"2026-03-13T04:18:23+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/19145158\/19-08-2025-feature.webp","type":"image\/webp"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix","name":"Pharma News | Precigen, REGENXBIO, Tonix","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/19145158\/19-08-2025-feature.webp","datePublished":"2025-08-19T09:22:49+00:00","dateModified":"2026-03-13T04:18:23+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Precigen\u2019s PAPZIMEOS; Tonix\u2019s Tonmya; REGENXBIO\u2019s RGX-121; SystImmune\u2019s Izalontamab Brengitecan; Soligenix\u2019s SGX945","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-precigen-regenxbio-tonix#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/19145158\/19-08-2025-feature.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/19145158\/19-08-2025-feature.webp","width":772,"height":482,"caption":"pharma-news-for-precigen-regenxbio-tonix"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/08\/19145158\/19-08-2025-feature-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome treatment market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fibromyalgia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hunter syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hunter Syndrome Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hunter Syndrome Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">mucopolysaccharidosis III<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market Insights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">non-small cell lung cancer treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recurrent respiratory papillomatosis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome<\/span>","<span class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome therapies<\/span>","<span class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome treatment<\/span>","<span class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome treatment market<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Fibromyalgia<\/span>","<span class=\"advgb-post-tax-term\">Hunter syndrome<\/span>","<span class=\"advgb-post-tax-term\">Hunter Syndrome Market<\/span>","<span class=\"advgb-post-tax-term\">Hunter Syndrome Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">mucopolysaccharidosis III<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market Insights<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline<\/span>","<span class=\"advgb-post-tax-term\">non-small cell lung cancer treatment<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">recurrent respiratory papillomatosis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 months ago","modified":"Updated 1 month ago"},"absolute_dates":{"created":"Posted on Aug 19, 2025","modified":"Updated on Mar 13, 2026"},"absolute_dates_time":{"created":"Posted on Aug 19, 2025 2:52 pm","modified":"Updated on Mar 13, 2026 9:48 am"},"featured_img_caption":"pharma-news-for-precigen-regenxbio-tonix\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33118"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33118\/revisions"}],"predecessor-version":[{"id":34691,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33118\/revisions\/34691"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33120"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33118"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33118"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}